| Study | Reason for exclusion |
|---|---|
| Adeboyeku 2001 | Not a relevant intervention ‐ tolerability study of differing dosages of nebulised colistin. |
| Amelina 2000 | Not a relevant intervention ‐ difference in quality of life between home versus hospital IV treatment. |
| Bittencourt 2016 | Not randomised. Retrospective cohort study. |
| Carswell 1987 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Chua 1990 | Not a relevant intervention ‐ used differing tonicities of inhaled antibiotics to assess airway responsiveness. |
| Coates 2011 | Pharmocokinetic study. |
| Conway 1996 | Not relevant participants ‐ did not differentiate between organisms causing exacerbation leading to inclusion into the trial. |
| Cooper 1985 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Dalbøge 2013 | An observational study. Not randomised. |
| Davis 1987 | Pharmocokinetic study. |
| Degg 1996 | Not a relevant intervention ‐ study on long‐term effects of gentamicin on hearing. Participants not selected on basis of microbial colonisation. |
| Dodd 1997 | Not a relevant intervention ‐ testing differences in lung function relating to tonicity of nebulised colistin. |
| Dodd 1998 | Not a relevant intervention ‐ a compliance study. No suitable control. |
| Flume 2015 | Not a relevant intervention ‐ safety evaluation of levofloxacin inhalation solution |
| Flume 2016 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Frederiksen 2006 | Not a relevant intervention ‐ not an eradication study |
| Garske 2004 | An observational study. |
| Geller 2004 | Pharmocokinetic study. |
| Goldfarb 1986 | Pharmocokinetic study. |
| Griffith 2008 | Pharmocokinetic/tolerability study. |
| Gulliver 2003 | Not a relevant intervention ‐ testing whether nebulised IV tobramycin solution induced cough or bronchoconstriction or both. |
| Hall 2015 | Observational study. No randomisation |
| Heininger 1993 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Hjelte 1988 | Not relevant participants ‐ investigated affect of home IV antibiotics for P. aeruginosa on quality of life. |
| Hodges 2014 | Not a relevant intervention |
| Huang 1979 | Not relevant participants ‐ did not differentiate between organisms causing exacerbation leading to inclusion into trial. |
| Huls 2000 | Pharmocokinetic study. |
| Junge 2001 | Not relevant participants ‐ investigating risk of ototoxicity or cochlea damage in once daily versus 3‐times daily IV tobramycin. |
| Kappler 2016 | An observational study. Not randomised. |
| Kapranov 1995 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Keel 2011 | Pharmocokinetic study. |
| Khorasani 2009 | Not a relevant intervention ‐ primary objective was not to eradicate MRSA |
| Knight 1979 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Labiris 2004 | Not a relevant intervention ‐ objective was to determine whether preservative containing inhaled tobramycin causes airway inflammation. |
| Loening ‐Bauke 1979 | Not a relevant intervention ‐ used cephalexin as prophylaxis. |
| Macfarlane 2007 | An observational study. |
| Maiz 1998 | A case report of one 10‐year old boy. |
| Nathanson 1985 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| NCT03181932 | Not relevant intervention ‐ primary outcome is change in lung function |
| Nolan 1982 | Not a relevant intervention ‐ prophylaxis rather than eradication. |
| Pai 2006 | Pharmocokinetic study. |
| Postnikov 2000 | Not relevant participants ‐ compared children with CF and aplastic anaemia |
| Postnikov 2001a | Not a relevant intervention ‐ describes risk of quinolone arthropathy in children. |
| Postnikov 2001b | Not a relevant intervention ‐ investigated the effect on growth with the addition of ciprofloxacin to the treatment of children with CF. |
| Ramstrom 2000 | Not a relevant intervention ‐ compared quality of life scores in patients who received pre‐made infusion devices compared to those who reconstituted drugs themselves. |
| Roberts 1993 | Pharmocokinetic study. |
| Romano 1991 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Rosenfeld 2006 | Pharmocokinetic study. |
| Sahl 1992 | Not relevant participants ‐ MRSA not required for entry into study. |
| Serisier 2004 | A case report of one 28‐year old man. |
| Shapera 1981 | Not relevant participants ‐ did not differentiate between MRSA and MSSA in inclusion criteria. Unclear how randomisation was achieved. |
| Sharma 2016 | Not a relevant intervention |
| Singh 2013 | Not relevant participants ‐ study of efficacy of interventions for pre‐pseudomonal pathogens |
| Smith 1997 | Pharmocokinetic study. |
| Solis 2003 | Retrospective study. |
| Stutman 1987 | Pharmacokinetic study of P. aeruginosa treatment. |
| Vallieres 2016 | An observational study. Not randomised. |
| Van Devanter 2014 | Not relevant participants ‐ trial of P. aeruginosa treatment. |
| Vanderhelst 2013 | An observational study. Not randomised. |
| Vitti 1975 | Pharmocokinetic study. |
| Wood 1996 | Not a relevant intervention ‐ compared aminoglycoside toxicity in twice and 3‐times daily dosing regimens. |
CF: cystic fibrosis IV: intravenous MRSA: meticillin‐resistant Staphylococcus aureus MSSA: meticillin‐sensitive Staphylococcus aureus P. aeruginosa: Pseudomonas aeruginosa